The use of venetoclax in the treatment of acute lymphoblastic leukemia—a systematic review
Therapeutic Advances in Medical Oncology
Published online on January 08, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:The 5-year overall survival rates in acute lymphoblastic leukemia (ALL) vary depending on the patient’s age group (from 93% to under 30%). However, in the case of relapsed/refractory ALL (R/R ALL), the complete remission (CR) rate in the ...
Background:The 5-year overall survival rates in acute lymphoblastic leukemia (ALL) vary depending on the patient’s age group (from 93% to under 30%). However, in the case of relapsed/refractory ALL (R/R ALL), the complete remission (CR) rate in the ...